Abstract: Disclosed are methods and complexes for increasing magnesium uptake in mammals. Increasing magnesium uptake in mammals is accomplished by concurrently administering one or more magnesium salts with one or more quaternary amines and/or phosphatides and one or more di- or tri-carboxylic acids.

Abstract: A method of producing volatilized fatty acids by heating a feedstock comprising at least one fat or oil in a reactor under inert vacuum to volatilize fatty acids, and removing volatilized fatty acids from bottoms residue comprising cross-linked oil. A system for stripping fatty acids from triglycerides, the system comprising a reactor, heating apparatus and a vacuum pump capable of pulling a vacuum in the range of from 1 kPa to 50 kPa on the reactor. A system for producing a hydrogenated product including a reactor comprising an inlet for a stream comprising triglycerides, an outlet for volatilized fatty acids, and an outlet for a cross-linked product, heating apparatus, a vacuum pump capable of pulling a vacuum in the range of from 1 kPa to 50 kPa on the reactor, and a hydrogenation reactor, wherein an inlet of the hydrogenation reactor is fluidly connected to the outlet for cross-linked product.

Abstract: The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g., a microbial contact kill time of 5 minutes or less. Further, the present technology provides a method of determining biocidally effective concentrations of biocidal compositions comprising at least one biocidal agent and at least one potentiator system.

Abstract: Described herein are compositions useful in anticancer treatment and prevention. The compositions are composed of (a) a dithiocarbamate metal chelate and (b) an amphiphile, wherein the amount of amphiphile is sufficient to produce a liposome or micelle. Methods for using the compositions in anticancer treatment and prevention are also described herein.

Abstract: The blood collection, processing and transfer by separation of discrete components containing additional citrate (at least about trisodium citrate 9% w/v) in one or other of collection or processing bag provides for enhanced yield and purity of cryoprecipitate. Inhibiting the activation or denaturation of blood components including blood cells and plasma proteins and with the removal of the activated and denatured components thereby improving safety and efficacy of end products. The inventive process is particularly suited to an improved extraction process to yield concentrated clotting factors from single donors or limited pools without use of chromatography. Following extraction the remaining cryoprecipitate can advantageously be formed into a fibrin fabric used in surgeries and in the treatment of wounds.

Abstract: Disclosed is a transdermally absorbable preparation in which the crystallization of a medicinal agent can be prevented even when the medicinal agent has poor solubility in a base material and is contained in the base material at a high concentration, and which exhibits excellent long-term stability and transdermal absorbability of the medicinal agent. By adding a complex of an organic acid and an organic acid salt and a medicinal agent to a base material, it becomes possible to produce a transdermally absorbable preparation in which the crystallization of the medicinal agent can be prevented and which has excellent preparation properties and transdermal absorbability. Also disclosed is use of a complex of an organic and an organic acid salt for preventing the crystallization of a medicinal agent in a transdermally absorbable preparation.

Abstract: A pharmaceutical composition comprising: a) a 5-HT1 agonist; b) an NSAID; and c) a disintegrant characterised in that the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, said composition optionally comprising one or more other pharmaceutically acceptable excipients.

Abstract: Provided are a method of manufacturing a solid microstructure capable of controlling multidrug release by mixing a biocompatible or biodegradable material with microparticles or nanoparticles and/or an emulsion as drug carriers and a solid microstructure structure manufactured using the same.

Abstract: Pharmaceutical compositions comprising (i) a dibasic amino acid ester or dibasic amino acid amide; (ii) a dicarboxylic acid; (iii) a pharmaceutically active compound or pharmaceutically acceptable salt thereof; and (iv) a pharmaceutically acceptable organic solvent. The pharmaceutical compositions form a depot when administered to an animal by injection that releases the pharmaceutically active compound over time.

Abstract: The present invention provides methods and compositions for delivery of taxanes in stable oil-in-water emulsion. The inventive emulsion formulation includes an oil phase, aqueous and emulsifier phases. The oil portion includes all or substantial amount of taxane, vegetable oil and medium chain triglycerides; aqueous phase includes an emulsion stabilizer; emulsifier phase reduces the surface tension between oil and aqueous phases to produce a stable oil-in-water emulsion. The inventive compositions produce minimal side effects upon administration.

Abstract: A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w/w) to about 24% (w/w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a lactic acid polymer or salt thereof having a weight-average molecular weight of 15000 to 50000 in which the content of polymers having molecular weights of 5000 or less is about 5% by weight or less, wherein the molar ratio of said hydroxynaphthoic acid or salt thereof to said physiologically active substance or salt thereof is from 3:4 to 4:3.

Abstract: A cosmetic transparent gel preparation that has high levels of transparency and hardness and favorable usability, as well as a gelling agent that is ideal for use in the cosmetic transparent gel preparation. The cosmetic transparent gel preparation contains an esterification reaction product obtained by reacting glycerol with a dibasic acid of 18 to 28 carbon atoms and a fatty acid of 8 to 28 carbon atoms (excluding dibasic acids), 12-hydroxystearic acid, and an oil component. The gelling agent contains an esterification reaction product obtained by reacting glycerol with a dibasic acid of 18 to 28 carbon atoms and a fatty acid of 8 to 28 carbon atoms (excluding dibasic acids), and 12-hydroxystearic acid.

Abstract: The invention concerns an aroma composition to reduce or suppress undesirable taste impressions, in particular a bitter, astringent and/or sweetener-like taste and/or long-lasting aftertaste of a sweetener, in the oral cavity, comprising (i) one or more sweeteners and (ii) ortho-coumaric acid (OCA) and optionally (iii) one or more specific bitter-masking aroma substances and/or flavourings and optionally (iv) one or more sweetness intensifying aroma substances and/or sweeteners and optionally (v) one or more inactive substances or carriers. The invention also concerns a preparation, containing such an aroma composition.

Abstract: A vesicle is produced by: a step of producing a W/O emulsion from an aqueous solution containing a substance to be entrapped in a vesicle in a dissolved or suspended state and an organic solvent phase containing a lipid having emulsification capacity, which can constitute the vesicle; a step of producing a W/O/W emulsion from the W/O emulsion and an external water phase solution of a water-soluble emulsifier, which does not destroy a vesicle lipid membrane; and a step of removing the organic solvent phase from the W/O/W emulsion, so as to form a vesicle. This method simultaneously achieves a high entrapment yield of an active ingredient and the control of a particle diameter.

Abstract: This invention relates to a composition that is mild to the skin containing a cosmetically acceptable oil; water; a cosmetically acceptable emulsifier having an HLB of from about 1 to about 25; and a preservative comprising an organic acid selected from the group consisting of benzoic acid, p-anisic acid, sorbic acid, lactic acid, acetic acid, formic acid, oxalic acid, tartaric acid, salicylic acid and citric acid; wherein said composition has a pH less than 5 and a buffer capacity of between about 0.001 and about 0.039.

Abstract: The present invention relates to a composition for treating keratin fibres, and in particular human keratin fibres such as the hair, comprising, in a cosmetically acceptable medium, one or more alkanolamines, one or more basic amino acids and one or more additional alkaline agents chosen from aqueous ammonia; ammonium salts of acids whose pKa at 25° C. is greater than 4; alkali metal or alkaline-earth metal hydroxides, carbonates, carbamates and hydrogen carbonates. The present invention also relates to processes for bleaching and/or dyeing keratin fibres, and also to multi-compartment devices or ‘kits’ for performing these processes.

Abstract: The present invention includes a method for delivering a medicament to a nail plate or nail bed that comprises providing a therapeutically effective amount of a medicament, etching the surface of the nail, and applying a medicament to the surface of the nail. A preferred embodiment of the present invention is directed to a method of treating a fungal infection of the fingernail or toenail. Also included in the present invention are the compositions (i.e., the etching compositions and/or the medicament compositions) used to treat the nail in accordance with the methods of the present invention.

Abstract: An eyelid scrub composition comprising polyhexamethylene biguanide (PHMB), 1,2-hexanediol, 1,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5. The composition can further comprise moisturizers and foam stabilizers. The composition can be combined with a fabric pad for use as an eyelid scrub, where the fabric pad is pre-moistened with the composition and packaged for use. The composition may be applied to the eyelid scrub and rubbed to induce foaming. The composition is produced by preparing a modified Ringer's solution and adding 1,2-hexanediol, 1,2-octanediol, and an effective amount of one or more pH stabilizing surfactants. The mixture is then heated and allowed to cool before polyhexamethylene biguanide is added.

Abstract: The present invention relates to long-wearing, non-aqueous based cosmetic compositions, and related dermatological, pharmaceutical or hygiene compositions. The present invention provides a non-aqueous based composition comprising one or a mixture of two or more emulsifiers.

Abstract: Effervescent powders comprising inhalable particles are disclosed, as are methods for preparing these powders. The inhalable carrier particles comprise an inorganic or organic carbonate, and an acid, and exhibit effervescence when exposed to water or humid air. The particles have a mass median aerodynamic diameter suitable for nasal, bronchial, or pulmonary administration. The inhalable particles may be used as carriers for active agents. The inhalable particles may also be used to enhance permeability of mucosal and surface barriers on an inner surface of the nose, mouth, airway, and/or lungs of a patient, as well as to loosen, thin, cleanse, and remove mucus and extrinsic surface materials from an inner surface of the nose, mouth, airway, and/or lungs of a patient in need thereof.

Abstract: Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Abstract: The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.

Abstract: The present invention relates to a pharmaceutical preparation, comprising a mixture of at least one pharmaceutical active ingredient, at least one alcohol component and at least one triglyceride component, in a plastic container, characterized in that the plastic has a water vapour permeability of no more than 3.0 g/m2/24 h (measured on a film 100 ?m thick at 40° c. and 90% relative humidity.

Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.

Abstract: The present invention provides nucleic acids encoding porcine taste receptors, polypeptides encoded by the nucleic acids, and methods of using the nucleic acids and polypeptides to identify compounds that enhance umami taste.

Abstract: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10?7 reciprocal second.

Abstract: This object of the invention is to provide an oil-in water emulsion cosmetic composition having fine sense of use and excellent dispersion stability, and does not occur twisting upon drying. In advance, a hydrophobicized powder is dispersed in an oil phase and processed with wet type disperser such as beads mill, dispersing solution is obtained. And then said dispersing solution and a water phase are processed with homomixer, an oil-in water emulsion composition having excellent sense of use and dispersibility of powder after applying to skin can be obtained. The dispersing stability of powder is extremely good by using a particular dispersant and a particular oil component. The dispersion stability of powder is further improved, and the precipitation and creaming of the emulsion particle can be solved by blending thickener having salt tolerance. Sticky feeling is solved by using succinoglycan as a thickener, and twisting is solved by plasticizing said succinoglycan.

Abstract: The present invention provides a base composition that allows for the formulation of non-irritating cosmetic and/or dermatological compositions. The base composition includes one or more of electrolyte, buffer, mild preservative, lubricant, or any combinations thereof. It is preferred that one or more of the above components are eye-safe and/or eye-compatible. The present invention also provides photoprotective cosmetic and/or dermatological compositions that include the base composition and one or more sunscreen active components and are non-irritating to mammalian eyes.

Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.

Abstract: A method for preparing a powder that includes perfuming or flavoring microcapsules of a perfuming or flavoring ingredient, a carrier material, and an explosion suppressant. The powder, when suspended in hot air during its preparation, has a reduced tendency for explosion. The explosion suppressant is selected from C1 to C12 carboxylic acids, their salts and mixtures of these.

Abstract: The invention relates to the use of ?-amino acid derivatives for improving the solubility of poorly soluble substances in water or aqueous solutions and to mixtures and preferred preparations.

Abstract: The invention relates to a novel solubilized small molecule topical formulation for the transdermal delivery of small molecule agents comprising: a small molecule agent, one or more micelle forming compounds, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the small molecule agent is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as the process for making the topical formulation.

Abstract: The present invention relates to a liquid additive product including at least one acid, intended, in combination with the water contained in a toilet flush cistern of a WC, to constitute an agent for treating polluting elements contained in the cistern, characterized in that the viscosity of the additive product is less than 500 mPa·s; wherein this acid is an organic acid, the concentration of which is at least equal to 30% by weight. It also relates to a treating agent consisting of the additive product and the water contained in the cistern; wherein the concentration of this additive product, in the water of the cistern, is between 100 ppm and 1000 ppm.

Abstract: The invention concerns a process for the production of a tableting excipient with the following process steps: At least two of the following components are made available: A filler/binding agent; A lubricant; A flow regulating agent; A disintegrant; The available components are mixed together.

Abstract: The invention provides ophthalmic compositions preserved using propionic preservative components alone or in combination with at least one additional preservative. In particular, an improvement in anti-microbial activity against bacteria is seen in addition to activity specific to fungal organisms and/or mold.

Abstract: A controlled release melatonin tablet having a slow release nucleus of melatonin, hydroxypropyl methylcellulose, a lubricant, a volume excipient and a glidant, wherein 95% of the melatonin is released within 5 hours in an oscillating tray containing gastric/intestinal juice at 37° C. and a fast release cortex coating on said nucleus of melatonin, hydroxypropyl methylcellulose and a volume excipient, wherein at least 95% of the melatonin is released within 10 minutes in an oscillating tray containing gastric/intestinal juice at 37° C.

Abstract: Disclosed herein are fumaryl diketopiperazine (FDKP) compositions and microparticles having a specific trans isomer content of about 45% to about 65%. The FDKP microparticles can comprise a drug such as an endocrine hormone, including, peptide, including, insulin, glucagon, parathyroid hormones and the like and can be used to make a powder formulation for pulmonary delivery of the drug.

Abstract: A method of controlling the amount of water in a polymer composition or substrate is provided. The method includes the step of adding to the polymer composition or substrate a low molecular weight unsaturated fatty acid which optionally includes a stabilizer composition for preventing oxidation of the low molecular weight unsaturated fatty acid.

Abstract: The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles.

Abstract: Disclosed are compounds that block off-notes in consumables and methods of blocking off-notes in consumables including off-notes provided by sweeteners such as stevioside, swingle extract, glyccerhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and rebaudioside A, and artificial sweeteners such as aspartame, saccharin, acesulfame K (Acesulfame potassium), sucralose and cyclamate.

Abstract: The present invention relates to oil-in-water nanoemulsions, processes for their preparation and their use as delivery vehicles for active components for use in opthalmological, dermatological, food, cosmetic, pharmaceutical, agrichemical, textile, polymer and chemical applications. The oil-in-water nanoemulsion comprises up to 40 volume % of an oil phase comprising at least 50 volume % of a triglyceride having a fatty acid chain length of 12 carbon atoms or greater and a hydrophilic non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) greater than 7; and an aqueous phase, in which the oil droplets have an intensity average size of less than 100 nm and the ratio of surfactant to oil is less than 1:1, more preferably 0.2 to 0.8:1.

Abstract: Disclosed herein are non-irritating ophthalmic emulsion compositions useful for treating ocular disorders including dry eye. More specifically, the ophthalmic compositions disclosed herein combine a high HLB surfactant and a low HLB surfactant together with an omega-3 fatty acid-containing oil having non-polar aliphatic side chains to form a therapeutic non-irritating eye drop.

Abstract: The present invention relates to an oil-in-water emulsion topical delivery system comprising an oil phase; an aqueous phase; phenoxyethanol; an effective exfoliatingamount of a hydrophobic hydroxycarboxylic acid; a non-ionic emulsifier having an HLB of from about 7 to about 10; and at least one skin-supporting ordermatopharmaceutically active agent.

Abstract: The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others.

Abstract: This invention relates to agricultural compositions, particularly pesticidal compositions which find particular use as a fungicide or herbicide composition. The pesticidal composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal activity; however, when combined with a fatty acid, the organic acid functions as a potent synergist for the fatty acid as a fungicide. Additionally, the pesticidal composition can include other components such as emulsifiers, adjuvants, surfactants and diluents. The pesticidal composition significantly reduces or prevents the fungal infection of cash crops including vegetables, fruits, berries, seeds, grains and at higher application rates, can also be used as a herbicide and/or harvest aid or desiccant for harvested crops such as potatoes. The addition of an emulsifier further enhances the herbicidal properties of the compositions.

Abstract: A pharmaceutical composition comprising a drug and a permeation enhancer that comprises a multi-carbon backbone having a functional group and also one or more side chains which have one or more carbon atoms and, optionally, one or more functional groups.

Abstract: The present invention relates to a method for forming an ophthalmic composition comprising mixing at least one hydroxide and pentetic acid with water and at least one oxidatively unstable component to form an ophthalmic composition comprising at least one salt of diethylenetriamine pentaacetic acid and a pH between about 6 and about 8.

Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

Abstract: A powder•particle dosage form obtained by granulating an excipient and/or a disintegrating agent with a liquid in which a bitter taste masking base is dissolved and/or suspended, and a drug having solubility in water (20° C.) of not higher than 1 g/mL is dissolved or suspended, or a tablet obtained by compressing the powder•particle dosage form could mask bitter taste of a drug.

Abstract: The present invention is directed to the use of a compound of Formula I and physiologically acceptable salts thereof wherein G1, G2, G3, R1, R2, R7, R3, R4, and R5 are defined herein. Compounds according to Formula I can be used to enhance a sweet taste produced by a tastant. The invention is also directed to compositions comprising a compound according to the above formula. Other aspects of the invention provide methods, compounds, and compositions for improved food products wherein the food product comprises a compound according to Formula I and a reduced amount of a sweet tastant.